USANew treatments and approvals
Approval letter issued in the USA for oral oveporexton for narcolepsy type 1
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The US Food and Drug Administration approved oveporexton tablets in a letter dated August 5, 2026. The approval is for adults with narcolepsy type 1 with cataplexy. The drug belongs to a new class that stimulates the orexin system in the brain. However, the drug's controlled substance classification had not yet been determined. For this reason, the drug can go on sale in the USA once the relevant agency publishes its decision.
What does it mean for patients and families?
The approval applies only to the USA and covers adults. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes. Treatment decisions are made with a sleep specialist.
Source
ABD Gıda ve İlaç Dairesi (FDA) · source page
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Narcolepsy type 1
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.